These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 11726321

  • 1. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L, Vidriales B, García-Laraña J, López A, Martínez R, Martín-Reina V, Tormo M, González-San Miguel JD, Lavilla E, García-Boyero R, Orfao A, San Miguel JF, PETHEMA Cooperative Group.
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [Abstract] [Full Text] [Related]

  • 2. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
    Suárez L, Vidriales MB, Moreno MJ, López A, García-Laraña J, Pérez-López C, Tormo M, Lavilla E, López-Berges MC, de Santiago M, San Miguel JF, Orfao A, PETHEMA Cooperative Group.
    Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
    [Abstract] [Full Text] [Related]

  • 3. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A.
    Clin Cancer Res; 2004 Nov 15; 10(22):7599-606. PubMed ID: 15569991
    [Abstract] [Full Text] [Related]

  • 4. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C, Hassan HT.
    Leuk Res; 2006 Mar 15; 30(3):296-302. PubMed ID: 16112192
    [Abstract] [Full Text] [Related]

  • 5. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.
    van Stijn A, van der Pol MA, Kok A, Bontje PM, Roemen GM, Beelen RH, Ossenkoppele GJ, Schuurhuis GJ.
    Haematologica; 2003 May 15; 88(5):497-508. PubMed ID: 12745269
    [Abstract] [Full Text] [Related]

  • 6. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL.
    Semin Hematol; 1997 Oct 15; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [Abstract] [Full Text] [Related]

  • 7. [Multidrug resistance markers monitoring in acute myeloid leukemia cells].
    Jankovicová K, Krejsek J, Kopecký O, Voglová J, Novosad J.
    Cas Lek Cesk; 2004 Oct 15; 143(7):471-5. PubMed ID: 15373290
    [Abstract] [Full Text] [Related]

  • 8. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L, Jarque I, Martín G, Sempere A, González-García Y, Gomis F, Pérez-Sirvent M, De La Rubia J, Sanz MA.
    Haematologica; 1998 Sep 15; 83(9):783-7. PubMed ID: 9825574
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C, Leonid K, Ruppert V, Schrappe M, Büchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dörken B, Ludwig WD.
    Haematologica; 2000 Jul 15; 85(7):711-21. PubMed ID: 10897123
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.
    Knaust E, Porwit-MacDonald A, Gruber A, Xu D, Peterson C.
    Haematologica; 2000 Feb 15; 85(2):124-32. PubMed ID: 10681718
    [Abstract] [Full Text] [Related]

  • 14. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
    Raspadori D, Damiani D, Michieli M, Stocchi R, Gentili S, Gozzetti A, Masolini P, Michelutti A, Geromin A, Fanin R, Lauria F.
    Haematologica; 2002 Nov 15; 87(11):1135-40. PubMed ID: 12414342
    [Abstract] [Full Text] [Related]

  • 15. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
    Cavalcanti GB, Vasconcelos FC, Pinto de Faria G, Scheiner MA, de Almeida Dobbin J, Klumb CE, Maia RC.
    Cytometry B Clin Cytom; 2004 Sep 15; 61(1):1-8. PubMed ID: 15351976
    [Abstract] [Full Text] [Related]

  • 16. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan 15; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 17. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T, Babusíková O.
    Neoplasma; 2006 Jan 15; 53(6):500-6. PubMed ID: 17167719
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
    Hassan HT.
    Leuk Res; 2004 Jul 15; 28(7):667-71. PubMed ID: 15158086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.